Fig. 2From: Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trialsOverall summary of risk of bias in the included studies. + : low risk of bias; −: high risk of bias; ?: unclear risk of biasBack to article page